Henlius company information, Employees & Contact Information

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)-Media 复宏汉霖

US FDA Accepts Biologics License Application (BLA) for HLX11, Biosimilar Candidate of Perjeta® (pertuzumab) 复宏汉霖

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Yahoo Finance

(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Business Wire

Henlius 2024 Second Scientific Advisory Board Meeting Held-Media 复宏汉霖

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of nsNSCLC 复宏汉霖

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe Yahoo Finance

Henlius and SVAX Forge Strategic Partnership in the MENAT Market-Media 复宏汉霖

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC 复宏汉霖

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 The AI Journal

Henlius Trastuzumab Receives FDA Approval in the United States-Media 复宏汉霖

Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA 复宏汉霖

Henlius Passes Its Second EU GMP Inspection-Media 复宏汉霖

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 复宏汉霖

Henlius to Showcase at BIO 2024-Media 复宏汉霖

Henlius to Make Its Debut at the World ADC Asia 2024-Media 复宏汉霖

Indonesian BPOM and KGbio Visit Henlius: Deepening Cooperation for Mutual Success-Media 复宏汉霖

Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX43 复宏汉霖

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX42-Media 复宏汉霖

Henlius lasofoxifene HLX78 IND Approved by NMPA-Media 复宏汉霖

Henlius Announces NMPA Approvals of Two ADC Candidates for IND-Media 复宏汉霖

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene-Media 复宏汉霖

Henlius Receives Approval in Japan for Phase 3 MRCT of Dual HER2 Blockade Therapy on First-Line HER2+ GC 复宏汉霖

Henlius’ Trastuzumab Plots Southeast Asia Expansion, to Enter Thailand and Philippines-Media 复宏汉霖

Henlius and Convalife Reach Global Strategic Cooperation on Neratinib-Media 复宏汉霖

Henlius Receives the FDA IND Approval for Its PD-L1-Targeting ADC Candidate HLX43-Media 复宏汉霖

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14-Media 复宏汉霖

Henlius Announces Successful Completion of Phase 1 PK Similarity Clinical Study of Denosumab HLX14 复宏汉霖

Henlius Announces Successful Completion of Phase 1 Clinical Study of Daratumumab HLX15 复宏汉霖

Henlius Receives Approval in Japan for Phase 3 MRCT of Anti-PD-1 mAb Serplulimab Combo on First-Line mCRC 复宏汉霖

Cell’s trends reviews journal published the regulatory differences of Henlius' biosimilar for approval between Europe and China-Media 复宏汉霖

Henlius to Present Latest Results on ADC and IO Therapies in Lung Cancer at 2025 WCLC-Media 复宏汉霖

Henlius and Eurofarma Entered into a License Agreement for Henlius' 3 Products in Latin America 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Ipilimumab Biosimilar HLX13-Media 复宏汉霖

Henlius and Organon Enter into a License and Supply Agreement for Henlius’ Two Biologics in ex-China Countries 复宏汉霖

IND Application of Henlius’ Pembrolizumab Biosimilar Approved by NMPA-Media 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Daratumumab Biosimilar HLX15-Media 复宏汉霖

Henlius and HanchorBio Enter into Strategic Collaboration to Spur Innovative Immunotherapies Development 复宏汉霖

Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX43-Media 复宏汉霖

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA-Media 复宏汉霖

Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53 IND Approved by NMPA-Media 复宏汉霖

Mr. Wenjie Zhang Appointed as Chairman of Henlius, Moving Towards a More Innovative Global Biopharmaceutical Company-Media 复宏汉霖

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia Business Wire

In-Depth Characterization for Methionine Oxidization in Complementary Domain Region by Hydrophobic Interaction Chromatography ACS Publications

Henlius Submitted Investigational New Drug Application for Its HLX12-Media 复宏汉霖

Making biologic medicines more accessible Nature

In-Depth Characterization of mAb Charge Variants by On-Line Multidimensional Liquid Chromatography-Mass Spectrometry ACS Publications

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies Business Wire